^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ABSK012

    i
    Other names: ABSK012
    Company:
    Abbisko
    Drug class:
    FGFR4 inhibitor
    Related drugs:
    1year
    Discovery & characterization of a next-generation FGFR4 inhibitor overcoming resistant mutations (AACR 2023)
    Efficacy studies were conducted in HCC xenograft models and mutant FGFR4-dependent xenograft models including a RMS PDX model harboring FGFR4 V550L mutation. ABSK012 demonstrated strong potency over multiple FGFR4 mutants that are insensitive to a first generation FGFR4 inhibitor BLU-554. ABSK012, presented here by Abbisko Therapeutics, is a highly potent, selective, and next-generation small molecule FGFR4 inhibitor overcoming FGFR4 mutations resistant to first-generation inhibitors. Its superior preclinical profile supports its fast-track development into clinic.
    Late-breaking abstract
    |
    FGF19 (Fibroblast growth factor 19) • FGFR4 (Fibroblast growth factor receptor 4) • AVEN (Apoptosis And Caspase Activation Inhibitor)
    |
    FGF19 overexpression • FGFR4 mutation • FGFR4 V550L • FGFR wild-type
    |
    fisogatinib (BLU-554) • ABSK012